Patents by Inventor Xufen Yu

Xufen Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds and methods of use
    Patent number: 11905291
    Abstract: Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 20, 2024
    Assignees: Icahn School of Medicine at Mount Sinai, The University of North Carolina at Chapel Hill
    Inventors: Jian Jin, Gang Wang, Jing Liu, Xufen Yu, Dongxu Li
  • SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA
    Publication number: 20230242496
    Abstract: Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.
    Type: Application
    Filed: June 15, 2021
    Publication date: August 3, 2023
    Applicant: Icahn School of Medicine At Mount Sinai
    Inventors: Jian JIN, Marta FILIZOLA, Aneel AGGARWAL, Samir PAREKH, Abhijeet KAPOOR, Shashidhar S. JATIANI, H. Umit KANISKAN, Jianping HU, Yudao SHEN, Fanye MENG, Lihuai QIN, Yulin HAN, Xufen YU, Chengwei ZHANG, Prashasti KUMAR, Rinku JAIN, Clement LEE
  • SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE
    Publication number: 20230167106
    Abstract: Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.
    Type: Application
    Filed: October 6, 2022
    Publication date: June 1, 2023
    Inventors: Jian Jin, Jing Liu, Ramon E. Parsons, Jia Xu, Xufen Yu
  • WD40 REPEAT DOMAIN PROTEIN 5 (WDR5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE
    Publication number: 20220348580
    Abstract: Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.
    Type: Application
    Filed: June 21, 2019
    Publication date: November 3, 2022
    Inventors: Jian Jin, Gang Wang, Jing Liu, Xufen Yu, Dongxu Li
  • Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
    Patent number: 11472799
    Abstract: Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 18, 2022
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Jian Jin, Jing Liu, Ramon E. Parsons, Jia Xu, Xufen Yu
  • SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE
    Publication number: 20200399266
    Abstract: Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 24, 2020
    Inventors: Jian Jin, Jing Liu, Ramon E. Parsons, Jia Xu, Xufen Yu